Overview

Atrial Fibrillation Progression Trial

Status:
Terminated
Trial end date:
2018-12-19
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine whether early radiofrequency (RF) ablation treatment, using the CARTO® 3 or CARTO® XP System, and THERMOCOOL® Catheter Family (including THERMOCOOL® SF or THERMOCOOL® SMARTTOUCH™) in subjects with paroxysmal atrial fibrillation (PAF), delays progression of atrial fibrillation (AF) compared with drug therapy (either rate or rhythm control) using current AF management guidelines.
Phase:
Phase 4
Details
Lead Sponsor:
Biosense Webster, Inc.
Treatments:
Anti-Arrhythmia Agents